Monographie - Tigecycline - Stabilis 4.0

Son güncelleme :
19/11/2024

Antibiyotik

Tigecycline

Enjeksiyon

Çözeltilerin stabilitesi

Karışımlardaki stabilitesi

Stabiliteyi etkileyen faktörler

Uyumluluk

Uygulama yöntemi

Kaynaklar

pdf

Kimyasal yapı

Ticari isim

Ticari isim

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Eticina	Meksika
Grexyl	Meksika
Linicetil	Meksika
Mrsacin	Türkiye
Tecygen	Şili
Tigecid	Türkiye
Tigecilina	Arjantin, Ekvador, Şili
Tigecycline	Kanada
Tigetop	Şili
Tizoxim	Arjantin
Tygacil	Almanya, Amerika Birleşik Devletleri, Arjantin, Avusturya, Belçika, Birleşik Arap Emirlikleri, Büyük Britanya, Danimarka, Ekvador, Finlandiya, Fransa, Hollanda, İrlanda, İspanya, İsveç, İsviçre, İtalya, İzlanda, Japonya, Kanada, Kolombiya, Lüksemburg, Macaristan, Malezya, Meksika, Norveç, Peru, Polonya, Portekiz, Romanya, Şili, Suudi Arabistan, Türkiye, Venezuela, yeni Zelanda, Yunanistan
Zomiprerin	Peru

Kaynaklar

Enjeksiyon

Kaynaklar : Tigecycline

	tip	yayın
2262	Dergi	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3128	Laboratuar	Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit Prostrakan 2013
3254	Dergi	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3332	Laboratuar	Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012
3531	Laboratuar	Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics Wockhardt 2014
3644	Laboratuar	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3674	Laboratuar	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3827	afiş	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	afiş	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	afiş	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3887	Dergi	Robiyanto R, Zaidi S.T.R, . Shastri M.D, Castelino R.L, Wanandy S.T, Jose M.D, . Patel R.P. Stability of Tigecycline in Different Types of Peritoneal Dialysis Solutions. Perit Dial Int 2016 ; 36:410-414.
4055	Dergi	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Dergi	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4528	Dergi	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4801	Dergi	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:

Mentions Légales